Its roles Owner Operator Offtaker
Bayer AG is a German multinational life science and chemical company headquartered in Leverkusen, founded in 1863. Its core businesses span Pharmaceuticals, Consumer Health, and Crop Science, with activities ranging from discovery and development to large‑scale manufacturing of active pharmaceutical ingredients (such as acetylsalicylic acid), over‑the‑counter health products, seeds, and crop protection chemicals. The company operates a global network of research, production, and distribution sites, including regional entities such as Bayer Taiwan Co., Ltd.
For the chemical industry, Bayer is notable for its pharmaceutical and agrochemical process chemistry and legacy in materials science; its materials business was separated as Covestro in 2015. Bayer is pursuing energy transition measures in its operations, including long‑term power and heat purchase agreements to support electrification and decarbonization at manufacturing sites, such as the acetylsalicylic acid plant in La Felguera, Spain.
Also known as Bayer Group, Bayer AG Taiwan Branch, Bayer Taiwan Co., Ltd., and Bayer Taiwan.
chemXplore tracks 23 projects involving Bayer, of which 6 are active.
Besides these 6, the record holds 16 completed projects and 1 cancelled.
Closest to start-up first.
1 more active project and the 17 that are completed, on hold or cancelled are in the record. See all 23 in chemXplore
Oral once-daily 50 mg FXIa inhibitor, given with antiplatelet therapy, cut ischemic stroke risk by 26% versus antiplatelets alone in a 12,327‑patient Phase III trial with similar major bleeding rates.
Uses molten-salt thermal storage, a 15 MW PPA and 2.5 MW PV; avoids ~6,500 tCO2/yr; >€18m investment and Spain's first large-scale heat-electrification project with storage.
China’s NMPA cleared an oral, reversible HER2‑targeting TKI for first‑line use in unresectable or metastatic HER2‑mutant NSCLC based on Phase I/II ORR and DOR data.
Pharma growth driven by Nubeqa and Kerendia; asundexian cleared in China; Group raises Pharma margin and Group EBITDA-before-special-items guidance, improves cash and debt outlook.
Jury cleared Monsanto on design‑defect, fraud and negligence claims in a three‑plaintiff case — the first Roundup trial after the Supreme Court’s June 2026 Durnell ruling.
First Factor XIa inhibitor worldwide approved to lower recurrent ischemic stroke risk after non‑cardioembolic stroke or high‑risk TIA in adults.
Interim Phase III DASL-HiCaP results show darolutamide added to ADT and radiation significantly improves metastasis-free survival versus placebo in high‑risk patients.
Analyses in patients with FSGS and IgAN found lower proteinuria and slower kidney function decline versus placebo.
active all projects
What each is building and closing, and the pipelines and grids between them, on one map.